| Assessment Status |
NCPE assessment ongoing |
| HTA ID |
23003 |
| Drug |
Voclosporin |
| Brand |
Lupkynis® |
| Indication |
Voclosporin is indicated in combination with mycophenolate mofetil for the treatment of adult patients with active class III, IV or V (including mixed class III/V and IV/V) lupus nephritis (LN). |
| Rapid review commissioned |
10/01/2023 |
| Rapid review completed |
10/02/2023 |
| Rapid review outcome |
A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of voclosporin compared with the current standard of care. |
| Full pharmacoeconomic assessment commissioned by HSE |
01/03/2023 |
| Pre-submission consultation with Applicant |
23/05/2023 |
| Full submission received from Applicant |
20/09/2023 |
| Preliminary review sent to Applicant |
24/04/2024 |
| NCPE assessment re-commenced |
31/05/2024 |
| Follow-up to preliminary review sent to Applicant |
02/09/2024 |
| NCPE assessment re-commenced |
09/09/2024 |
| Factual accuracy sent to Applicant |
25/10/2024 |
| NCPE assessment re-commenced |
05/11/2024 |
